Merck & Co Inc (Ticker: MRK) recently saw its shares surpass the average analyst 12-month target price of $92.53, trading at $93.13 per share. This uptick follows assessments from 15 analysts contributing to the target, with a standard deviation of $10.769. The highest price target stands at $110.00, while the lowest is $70.00.
As of now, there are eight strong buy ratings and eight hold ratings for Merck, with no buy or sell ratings assigned. The average analyst rating remains consistent at 2.0 on a scale where 1 is Strong Buy and 5 is Strong Sell. Investors may now reevaluate their positions considering potential future gains or whether the stock might be overvalued.
